MarketPeel
Insider Trading Intelligence
Pricing
…
JM

James Mulay

CGON
DIRECTOR · CG ONCOLOGY, INC. · CIK 0001684531
FILING MIX · LIFETIME36%/64%
BUYS
16
SELLS
29
TOTAL VALUE
$7.77M
COMPANIES
1
ACTIVE SINCE
Oct 2024
HOLDINGS NOW
24,165
AVG SELL PX
$50.97
TRADE KIND
SHOWING 45 / 45
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons · 30 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by James Mulay, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+46.15%-1.28%+0.06%-1.34%-0.76%—
14d13+46.15%+3.40%+0.08%+3.32%+2.60%—
30d13+30.77%+5.79%+2.60%+3.19%+6.41%—
60d13+15.38%+10.16%+3.50%+6.66%+13.82%—
90d13(1 pending)+33.33%+14.29%+4.19%+10.10%+14.80%—
180d13(3 pending)+0.00%+67.33%+3.36%+63.97%+75.27%—
1y13(13 pending)——————
2y13(13 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CGON · 24,165 shares · as of Jul 10, 2026
06,75413,50820,26127,01520252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 16 buys / 29 sellsCOVERAGE · 8 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CGON
CG ONCOLOGY, INC.
PURCHASE
24,165$26.63$643.5K24,165Jul 10, 2026Jul 14, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
24,165$75.16$1.82M0Jul 10, 2026Jul 14, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
24,165——0Jul 10, 2026Jul 14, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
1,310$12.59$16.5K1,310Jun 15, 2026Jun 16, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
1,310$60.12$78.8K0Jun 15, 2026Jun 16, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
1,310——2,620Jun 15, 2026Jun 16, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
654$3.72$2.4K654Jun 15, 2026Jun 16, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
654——0Jun 15, 2026Jun 16, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
654$60.12$39.3K0Jun 15, 2026Jun 16, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
9,354——9,354Jun 4, 2026Jun 5, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
15,600$36.63$571.4K15,600Apr 17, 2026Apr 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
15,600——0Apr 17, 2026Apr 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
15,600$73.01$1.14M0Apr 17, 2026Apr 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
1,310$12.59$16.5K1,310Mar 16, 2026Mar 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
654$63.50$41.5K0Mar 16, 2026Mar 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
654$3.72$2.4K654Mar 16, 2026Mar 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
1,310$63.50$83.2K0Mar 16, 2026Mar 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
654——654Mar 16, 2026Mar 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
1,310——3,930Mar 16, 2026Mar 17, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
654$44.16$28.9K0Jan 9, 2026Jan 13, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
10,491$12.59$132.1K10,491Jan 9, 2026Jan 13, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
654$3.72$2.4K654Jan 9, 2026Jan 13, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
10,491——5,240Jan 9, 2026Jan 13, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
654——1,308Jan 9, 2026Jan 13, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
10,491$52.99$555.9K0Jan 9, 2026Jan 13, 2026 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
5,903——1,962Oct 9, 2025Oct 10, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
5,903$43.99$259.7K0Oct 9, 2025Oct 10, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
5,903$3.72$22.0K5,903Oct 9, 2025Oct 10, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
12,755$1.82$23.2K12,755Sep 29, 2025Sep 30, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
12,755$39.19$499.9K0Sep 29, 2025Sep 30, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
12,755——0Sep 29, 2025Sep 30, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
3,574$1.82$6.5K3,574Sep 19, 2025Sep 22, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
3,574$38.99$139.4K0Sep 19, 2025Sep 22, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
3,574——12,755Sep 19, 2025Sep 22, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
19,112——16,329Sep 18, 2025Sep 22, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
19,112$39.01$745.6K0Sep 18, 2025Sep 22, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
19,112$1.82$34.8K19,112Sep 18, 2025Sep 22, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
12,342$30.47$376.1K14,673Sep 5, 2025Sep 8, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
3,113$33.22$103.4K0Sep 5, 2025Sep 8, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASE
27,015$0.60$16.2K27,015Sep 5, 2025Sep 8, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE
27,015——0Sep 5, 2025Sep 8, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
7,465$32.64$243.7K3,113Sep 5, 2025Sep 8, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
4,095$31.42$128.7K10,578Sep 5, 2025Sep 8, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
24,165——24,165Jun 5, 2025Jun 5, 2025 ↗View →
CGON
CG ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
15,600——15,600Oct 4, 2024Oct 7, 2024 ↗View →
Other insiders · CGON
Loading peer insiders…
About this filer
CIK 0001684531
ROLE
Director
PRIMARY
CGON
COMPANIES
1
ACTIVE SINCE
Oct 2024
MARKETPEEL · /INSIDER/0001684531DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback